Quest Diagnostics (DGX) Fundamental Analysis: Revenue, Earnings & Valuation

5.69 / 10

Netural

Fundamental rating is neutral (5.7/10). Cash position is strong (Cash‑MV high, Cash‑UP positive), but revenue growth and basic EPS YoY lag peers. Inventory turnover is efficient. Overall, the balance sheet supports modest confidence but growth drivers are limited.

Analysis Checks(7/10)

Revenue-MV

Value2.38

Score1/3

Weight4.23%

1M Return2.00%

Net cash flow from operating activities per share (YoY growth rate %)

Value42.66

Score2/3

Weight8.16%

1M Return3.60%

Inventory turnover ratio

Value39.10

Score3/3

Weight20.42%

1M Return7.73%

Net income-Revenue

Value-0.12

Score3/3

Weight21.54%

1M Return7.62%

Basic earnings per share (YoY growth rate %)

Value14.01

Score1/3

Weight2.18%

1M Return0.92%

Total profit (YoY growth rate %)

Value13.90

Score2/3

Weight7.28%

1M Return3.08%

Net cash flow from operating activities (YoY growth rate %)

Value41.38

Score2/3

Weight8.71%

1M Return3.84%

Cash-UP

Value-0.24

Score2/3

Weight2.51%

1M Return0.89%

Diluted earnings per share (YoY growth rate %)

Value13.78

Score1/3

Weight1.82%

1M Return0.78%

Cash-MV

Value2.04

Score3/3

Weight23.15%

1M Return8.03%

Is DGX undervalued or overvalued?

DGX scores 5.69/10 on fundamentals and holds a Fair valuation at present. Backed by its 13.99% ROE, 9.48% net margin, 21.95 P/E ratio, 2.99 P/B ratio, and 14.01% earnings growth, these metrics solidify its Netural investment rating.